Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine

Title:Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine

Volume: 20 Issue: 14

Author(s): Samantha Y. A. Terry, Mark Rijpkema, Keelara Abiraj, Winette T. van der Graaf, Wim J. Oyen and Otto C. Boerman

Affiliation:

Keywords: Angiogenesis, radiolabeled imaging probes, personalized medicine, integrin α_v β_3, VEGF, RGD.

Abstract: Angiogenesis is essential for tumor growth and inhibiting angiogenesis has become an important therapeutic strategy in clinical oncology. Nonetheless, the mechanisms behind anti-angiogenic therapeutics as well as resistance to these drugs remain unclear. With a lack of validated genetic or molecular biomarkers for anti-angiogenic responsiveness, novel methods to identify responsive patients are required. Non-invasive nuclear imaging would allow the elucidation of the basic drug mechanisms as well as resistance routes and aid the personalization of anti-angiogenic therapy by enabling target expression quantification prior to and during treatment. This review focuses on the development of radiolabeled probes to image four key proteins expressed during angiogenesis, namely vascular endothelial growth factor and its receptor, integrin α_v β_3, the extracellular domain of fibronectin and matrix metalloproteases, and how these probes can be utilized for personalized anti-angiogenic therapy.

Cite this article as:

Terry Y. A. Samantha, Rijpkema Mark, Abiraj Keelara, Graaf T. van der Winette, Oyen J. Wim and Boerman C. Otto, Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113196660665